Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-04-04Clinical Trial Update: Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL) [Phase 2]
This document provides an update on a Phase 2 trial evaluating rituximab with CVP chemotherapy plus interferon for follicular non-Hodgkin ly…
-
CLINICAL_TRIALS trial_result · 2016-03-30Clinical Trial Update: Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating mobilization and collection of peripheral hematopoietic stem cells using Plerixafor plus G-CSF in Japanese patients…
-
CLINICAL_TRIALS trial_result · 2016-03-30Clinical Trial Update: A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating ocrelizumab in participants with follicular non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2016-03-15Clinical Trial Update: The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas [Phase 1]
A Phase 1 clinical trial evaluating the combination of everolimus (Rad001) and rituximab in patients with Non-Hodgkin lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2016-03-10Clinical Trial Update: Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial sponsored by the National Cancer Institute evaluated alisertib for relapsed or refractory peripheral T-cell non-Hodgkin lymp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating safety and efficacy of POL6326 for mobilization and transplant in hematologic malignancies has completed…
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer [Phase 2]
Phase 2 trial update of Basiliximab to prevent graft-versus-host disease after nonmyeloablative allogeneic transplantation in blood cancers;…
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release [Phase 2]
Phase 2 trial evaluating mesna to prevent doxorubicin-induced plasma protein oxidation and TNF-α release in patients with breast cancer or n…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
This ClinicalTrials.gov entry notes completion and posting of results for a trial evaluating rituximab in combination with CHOP or CHOP-like…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
A completed clinical trial update evaluating Ribomustin (bendamustine) as second-line therapy for relapsed or refractory indolent B-cell non…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial update evaluating Zevalin in combination with BuCyE high-dose therapy for B-cell non-Hodgkin lymphoma; the study status is c…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Gemcitabine for Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial evaluating gemcitabine for marginal zone lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-02-15Clinical Trial Update: Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom [Phase 2]
A Phase 2 study evaluating transplantation using Zevalin (ibritumomab tiuxetan) with BEAM conditioning in patients with refractory diffuse l…
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy [Phase 2]
This Phase 2 study from Memorial Sloan Kettering Cancer Center evaluated a myeloablative conditioning regimen with total body irradiation fo…
-
CLINICAL_TRIALS trial_result · 2016-02-08Clinical Trial Update: Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial results for lenalidomide, rituximab, cyclophosphamide, and dexamethasone in previously untreated low-grade non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2016-02-01Clinical Trial Update: Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial update examining chemotherapy, radiation therapy, rituximab, and umbilical cord blood transplantation for B-cell non-…
-
CLINICAL_TRIALS trial_result · 2016-02-01Clinical Trial Update: Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor [Phase 2]
Phase II study evaluating a myeloablative conditioning regimen of busulfan, melphalan, and fludarabine followed by an allogeneic hematopoiet…
-
CLINICAL_TRIALS trial_result · 2016-02-01Clinical Trial Update: Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT [NA]
This trial assessed whether rituximab (Rituxan) can prevent EBV-associated lymphoproliferative disorder after T-cell-depleted unrelated or H…
-
CLINICAL_TRIALS trial_result · 2016-02-01Clinical Trial Update: Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab
A completed clinical trial update on patients with low-grade Non-Hodgkin lymphoma treated with iodine-131 labeled tositumomab.
-
CLINICAL_TRIALS trial_result · 2016-01-25Clinical Trial Update: LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma [Phase 2]
Phase 2 trial update for LSA4 protocol in advanced pediatric and adolescent Non-Hodgkin's Lymphoma completed with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-01-15Clinical Trial Update: Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in combination with outpatient therapy for CD20+ non-Hodgkin lymphoma; the study has completed.
-
CLINICAL_TRIALS trial_result · 2016-01-14Clinical Trial Update: Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases [Phase 2]
Phase 2 trial evaluating total body irradiation with fludarabine-based conditioning followed by haploidentical transplantation for hematolog…
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: Efficacy Study of Outpatient Therapy for Lymphoma [Phase 2]
A Phase 2 efficacy trial evaluating outpatient therapy for lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma [Phase 2]
A Phase 2 clinical trial evaluated the efficacy and treatment-related toxicity of a new regimen for lymphoma, including Non-Hodgkin's Lympho…
-
CLINICAL_TRIALS trial_result · 2016-01-07Clinical Trial Update: Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 safety and efficacy study of AME-133v, an anti-CD20 monoclonal antibody, for Non-Hodgkin lymphoma has completed.